Chronic ipamorelin treatment in young female rats maintained GH-releasing effectiveness without desensitizing somatotroph cells, though it modulated GHRH and somatostatin receptor expression.
No desensitizationChronic ipamorelin preserved pituitary GH responsiveness despite receptor expression changes — the drug maintains its effectiveness over time
What the researchers found
Chronic ipamorelin treatment maintained somatotroph GH-releasing responsiveness without desensitization, though GHRH and somatostatin receptor expression were modulated — adaptive changes that preserved overall drug effectiveness.
Why it matters
Maintaining effectiveness during chronic use is essential for GH secretagogues to serve as long-term GH replacement therapy. This study provides reassurance that ipamorelin doesn't lose its punch.
How the study worked
Animal study in young female rats with chronic ipamorelin treatment. Pituitary somatotroph responsiveness tested ex vivo. GHRH receptor and somatostatin receptor expression measured by molecular techniques.
What this study cannot tell us
Young female rats; may not predict adult human responses. Receptor expression changes suggest adaptive mechanisms that could eventually affect efficacy with very long-term use.
How to read the evidence
Preliminary animal evidence with functional and molecular characterization of chronic treatment effects on the GH axis.
When this study was published
Published in 2002. Ipamorelin's sustained efficacy has been noted in multiple studies, supporting its clinical development for long-term use.
The bigger picture
Drug tolerance is a major barrier to chronic peptide therapy. Ipamorelin's maintained effectiveness suggests it could work long-term, unlike drugs that lose efficacy through receptor desensitization.
Questions still open
- Does ipamorelin maintain effectiveness over years of use in humans?
- Do the receptor expression changes eventually limit response?
- Is ipamorelin's sustained efficacy unique or shared by other GH secretagogues?
Common questions
Does ipamorelin stop working over time?
Is this different from other GH peptides?
Read the original research
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.
Histology and histopathology, 17(3), 707-14
Citation
Jiménez-Reina, L; Cañete, R; de la Torre, M J; Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.. Histology and histopathology, 17(3), 707-14. https://doi.org/10.14670/HH-17.707